What does the evidence say about Baicalin Cognition Randomized Trial?

Updated October 2026

Quick Answer

Baicalin Cognition Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3 4 Ischemic stroke accounts for approximately 87% of all reported stroke cases and is frequently associated with cognitive dysfunction [,].

Key Takeaways

  • 011 2 3 4 Ischemic stroke accounts for approximately 87% of all reported stroke cases and is frequently associated with cognitive dysfunction [,]. [Liu Jianfeng (2020)]
  • 02In the mouse model of cerebral hypoperfusion, consumption of multistrain probiotics can alleviate hippocampal injury and deficits in spatial and learning memory, thereby providing more evidence for the key role of gut microbiota in brain function []. [Liu Jianfeng (2020)]
  • 03Figure 1A Figure 1B 1C Figure 1D Figure 1E Figure 1F 1G The object recognition test results showed that the preferential index after training for 1h was significantly reduced in the mice subjected to repeated cerebral ischemia-reperfusion (model group) compared with the control mice (). [Liu Jianfeng (2020)]
  • 04Currently, the standard treatment for acute ischemic stroke is intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) []. [Liu Jianfeng (2020)]
The current Migaku evidence database contains 2 reusable source documents for Baicalin Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - 1 2 3 4 Ischemic stroke accounts for approximately 87% of all reported stroke cases and is frequently associated with cognitive dysfunction [,]. [Liu Jianfeng (2020); evidence level 4] - In the mouse model of cerebral hypoperfusion, consumption of multistrain probiotics can alleviate hippocampal injury and deficits in spatial and learning memory, thereby providing more evidence for the key role of gut microbiota in brain function []. [Liu Jianfeng (2020); evidence level 4] - Figure 1A Figure 1B 1C Figure 1D Figure 1E Figure 1F 1G The object recognition test results showed that the preferential index after training for 1h was significantly reduced in the mice subjected to repeated cerebral ischemia-reperfusion (model group) compared with the control mice (). [Liu Jianfeng (2020); evidence level 4] - Currently, the standard treatment for acute ischemic stroke is intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) []. [Liu Jianfeng (2020); evidence level 4] - Conclusion Overall, the results of the present study indicated that BAI is a promising neuroprotective compound for use in the prevention and treatment of microglia-mediated neuroinflammation during AD progression. [Jin X (2019); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Baicalin ameliorates neuropathology in repeated cerebral ischemia-reperfusion injury model mice by remodeling the gut microbiota
  2. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway.